Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG ...

Pharmac estimates the new approach will save approximately 3,700 infusion hours annually, easing pressure on oncology ...

Despite major advances in targeted therapy, chronic lymphocytic leukemia (CLL) remains largely incurable. Resistance to ...

Patients with chronic lymphocytic leukemia show higher risks for skin cancer, as well as skin cancer-specific metastasis and ...

Targeting 2026 IND submission for bexobrutideg in inflammatory and autoimmune indications with a new tablet formulation Continuing advancement of targeted protein degraders of IRAK4 in Phase 1 and ...

New research is helping to change the way investigators and clinicians think about and treat Richter transformation (RT) in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic ...

CLL is linked to higher skin cancer risk and worse outcomes. Learn more about this large cohort study and its clinical ...

Cardiovascular comorbidities were equally prevalent in full-dose and reduced-dose groups, suggesting well-controlled cardiovascular disease need not contraindicate standard dosing.

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...

Jaypirca is a targeted therapy for CLL and other specific cancers. It is known as a Bruton’s tyrosine kinase inhibitor (BTK inhibitor). BTK is an enzyme that helps certain types of cancer cells grow.

The FDA has approved oral acalabrutinib (Calquence, AstraZeneca) in combination with venetoclax (Venclexta, AbbVie and Genentech) for the first-line treatment of adults with chronic lymphocytic ...